65 i b, drugs, pharmaceuticals, & hematology related products, FSS contract award

Active Awarded Last action

Contract number
36F79724D0180
Awardee
Awarding agency
Task orders
0

Award facts

Opportunity
  • 65IB Solicitation number
Last date to order 43% complete
IDV ceiling
$37,266,560.00
Award type
Multiple award
Who can order
All agencies
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition Negotiated Proposal / Quote
Pricing
Fixed Price with Economic Price Adjustment

Award details come from SAM.gov/FPDS.

About this IDV

Intercept Pharmaceuticals Inc. received a multiple-award Federal Supply Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB) from the Department of Veterans Affairs, Veterans Integrated Service Network 12, with an award date of September 1, 2024, and a ceiling value of $37.3 million through August 31, 2029. This contract encompasses the supply of drugs, pharmaceuticals, and hematology-related products with pricing aligned to 2026 Public Law updates. As a prime contractor on the GSA Pharmaceuticals and Drugs Federal Supply Schedule, Intercept will provide pharmaceutical products to the Veterans Health Administration to support clinical needs across the veterans healthcare system. The contract operates as an indefinite delivery vehicle, allowing the Department of Veterans Affairs to issue delivery orders and task orders to procure specified pharmaceutical items on an as-needed basis throughout the contract performance period.

Under this Federal Supply Schedule contract, Intercept Pharmaceuticals Inc. is positioned to supply pharmaceutical products to support veteran patient populations managed through the Department of Veterans Affairs healthcare networks. The contract structure enables efficient procurement of required medications while maintaining pricing consistency across the contract period. Additionally, Intercept holds a related single-award Blanket Purchase Agreement with the Department of Veterans Affairs National Acquisition Center, initially valued at $21 million and awarded October 17, 2024, which was designated for Ocaliva (obeticholic acid) 5mg tablets for treatment of primary biliary cholangitis in veterans with inadequate response to ursodeoxycholic acid therapy. However, this Blanket Purchase Agreement was subsequently cancelled due to the product's withdrawal from the United States market, eliminating the availability of this treatment option and requiring the Veterans Health Administration to identify alternative therapeutic protocols for affected patient populations.

IDV awards

IDV Agency Ceiling Awarded
36E79725A0001 BPA for ocaliva National Acquisition Center (VA) $21,000,000

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00004 · 2026 public law pricing updates $0
Supplemental Agreement for work within scope P00002 · Tracking customer change $0
Supplemental Agreement for work within scope P00001 · 2025 public law pricing updates $0
Original award $0

Quick answers

Who was awarded contract 36F79724D0180?

36F79724D0180 was awarded to Intercept Pharmaceuticals Inc. by Veterans Integrated Service Network 12 (Veterans Health Administration) on September 1, 2024.

How much is contract 36F79724D0180 worth?

36F79724D0180's own ceiling is $37,266,560.

Who can order from contract 36F79724D0180?

36F79724D0180 is a multiple award federal supply schedule. All agencies can place orders on it.

Is contract 36F79724D0180 part of a contract vehicle?

Yes. 36F79724D0180 is part of Pharmaceuticals and Drugs (FSS-61-IB).

Was contract 36F79724D0180 competed?

The extent of competition for 36F79724D0180 was full and open competition.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV